博瑞医药
(688166)
| 流通市值：256.91亿 | | | 总市值：256.91亿 |
| 流通股本：4.30亿 | | | 总股本：4.30亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 324,934,750.4 | 1,223,640,129.98 | 874,249,705.24 | 537,438,662.14 |
| 营业收入 | 324,934,750.4 | 1,223,640,129.98 | 874,249,705.24 | 537,438,662.14 |
| 二、营业总成本 | 329,340,975.82 | 1,204,341,010.5 | 859,671,361.36 | 549,542,369.7 |
| 营业成本 | 140,464,532.97 | 601,611,553.11 | 424,926,677.5 | 275,665,557.36 |
| 税金及附加 | 3,642,886.72 | 13,029,854.37 | 8,904,941.78 | 5,473,900.07 |
| 销售费用 | 12,018,781.88 | 78,021,529.36 | 61,771,544.27 | 39,649,202.67 |
| 管理费用 | 32,025,530.98 | 154,505,701.98 | 113,542,725.05 | 70,728,331.17 |
| 研发费用 | 120,151,095.89 | 304,947,050.73 | 216,428,186.84 | 138,287,639.33 |
| 财务费用 | 21,038,147.38 | 52,225,320.95 | 34,097,285.92 | 19,737,739.1 |
| 其中:利息费用 | 18,582,633.2 | 62,957,015.06 | 48,369,730.43 | 29,026,886.6 |
| 其中:利息收入 | 311,493.41 | 5,547,241.5 | 7,958,528.43 | 2,966,294.54 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 2,589,650.9 | 13,784,762.71 | 1,513,855.64 | 1,585,851.81 |
| 加:投资收益 | -796,203.85 | -19,321,426.73 | -11,753,984.38 | -5,427,848.31 |
| 资产减值损失(新) | 729,415.71 | -17,497,638.54 | -2,756,862.56 | -2,766,161.91 |
| 信用减值损失(新) | -8,653,096.6 | -20,274,363.81 | 3,127,119.97 | 3,496,034.52 |
| 其他收益 | 6,847,801.56 | 38,673,662.95 | 18,064,813.94 | 10,393,707.71 |
| 四、营业利润 | -3,688,657.7 | 14,664,116.06 | 22,773,286.49 | -4,822,123.74 |
| 加:营业外收入 | 263,079.51 | 207,522.2 | 178,434.88 | 135,150.78 |
| 减:营业外支出 | 51,321.48 | 962,807.6 | 536,922.71 | 334,252.39 |
| 五、利润总额 | -3,476,899.67 | 13,908,830.66 | 22,414,798.66 | -5,021,225.35 |
| 减:所得税费用 | -12,978,304.71 | -23,045,408.52 | -8,971,726.09 | -6,678,301.82 |
| 六、净利润 | 9,501,405.04 | 36,954,239.18 | 31,386,524.75 | 1,657,076.47 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 9,501,405.04 | 36,954,239.18 | 31,386,524.75 | 1,657,076.47 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 9,293,715.39 | 54,514,680.92 | 50,320,017.34 | 17,173,195.68 |
| 少数股东损益 | 207,689.65 | -17,560,441.74 | -18,933,492.59 | -15,516,119.21 |
| 扣除非经常损益后的净利润 | 4,211,386.68 | 26,089,388.86 | 46,172,260.19 | 14,368,619.87 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.02 | 0.13 | 0.12 | 0.04 |
| (二)稀释每股收益 | 0.02 | 0.13 | 0.12 | 0.04 |
| 八、其他综合收益 | -327,248 | 36,676,515.56 | -2,579,713.14 | -2,579,713.14 |
| 归属于母公司股东的其他综合收益 | -327,248 | 36,676,515.56 | -2,579,713.14 | -2,579,713.14 |
| 九、综合收益总额 | 9,174,157.04 | 73,630,754.74 | 28,806,811.61 | -922,636.67 |
| 归属于母公司股东的综合收益总额 | 8,966,467.39 | 91,191,196.48 | 47,740,304.2 | 14,593,482.54 |
| 归属于少数股东的综合收益总额 | 207,689.65 | -17,560,441.74 | -18,933,492.59 | -15,516,119.21 |
| 公告日期 | 2026-04-30 | 2026-03-20 | 2025-10-31 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |